Physician profile
Christopher E Avendano
NPI 1003868126
$975.88
in general payments reported to CMS, 2019-2025
17 companies · $74.19 in 2025
The $74.19 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $220 · 2021: $162 · 2022: $165 · 2023: $145 · 2025: $74.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $219.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $231.56 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.52 | 2019-2021 | |
| Genzyme Corporation | $114.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $99.04 | 2019-2023 | Fasenra |
| United Therapeutics Corporation | $62.72 | 2019-2023 | Tyvaso |
| Mylan Specialty L.P. | $48.88 | 2019-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $48.00 | 2021-2025 | Opsumit |
| Jazz Pharmaceuticals INC. | $34.43 | 2019-2022 | |
| Baxter Healthcare | $33.24 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Gilead Sciences, INC. | $27.36 | 2022 | |
| Harmony Biosciences LLC | $26.37 | 2020 | |
| Insmed, INC. | $25.60 | 2023 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $22.19 | 2020 | |
| Circassia INC. | $18.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.85 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $14.52 | 2019 | |
| Astellas Pharma US INC | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Avendano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.